PowerUp Acquisition Corp. (PWUP)
| Previous close | 11.20 |
| Open | 11.19 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 11.19 - 11.19 |
| 52-week range | 10.07 - 11.80 |
| Volume | |
| Avg. volume | 14,978 |
| Market cap | 100.612M |
| Beta (5Y monthly) | -0.00 |
| PE ratio (TTM) | 48.65 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
PowerUp Acquisition Corp. and Visiox Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form S-4 to the SEC in Connection with the Previously Announced Proposed Business Combination
Tarrytown, NY and New York, NY, Jan. 29, 2024 (GLOBE NEWSWIRE) -- PowerUp Acquisition Corp. (“PowerUp”) (Nasdaq: PWUP) and Visiox Pharmaceuticals, Inc. (“Visiox”), a commercial-stage biopharmaceutical company, today announced that PowerUp has filed with the U.S. Securities and Exchange Commission (“SEC”) a registration statement on Form S-4 in connection with the previously announced proposed business combination between PowerUp and Visiox (the “Business Combination” or the “Transaction”). The c
- GlobeNewswire
Visiox Pharmaceuticals, Inc., a Commercial-Stage Biopharmaceutical Company to be Listed on Nasdaq Through a Business Combination with PowerUp Acquisition Corp.
Tarrytown, NY and New York, NY, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Visiox Pharmaceuticals, Inc. (“Visiox” or the “Company”), a commercial-stage biopharmaceutical company, and PowerUp Acquisition Corp. (“PowerUp”) (Nasdaq: PWUP) today announced the execution of a definitive agreement for a business combination (the “Transaction” or the “Business Combination”) that would result in Visiox becoming a publicly traded company on the Nasdaq Capital Market (“Nasdaq”). The business combination is expected
